세계의 LBP(라이브 바이오테라퓨틱스) 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Live Biotherapeutics Market - Scope of Report

TMR's report on the global live biotherapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global live biotherapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global live biotherapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the live biotherapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global live biotherapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global live biotherapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global live biotherapeutics market.

The report delves into the competitive landscape of the global live biotherapeutics market. Key players operating in the global live biotherapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global live biotherapeutics market profiled in this report.

Key Questions Answered in Global live biotherapeutics Market Report:

• What is the sales/revenue generated by live biotherapeutics across all regions during the forecast period?
• What are the opportunities in the global live biotherapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Live Biotherapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global live biotherapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global live biotherapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global live biotherapeutics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Live Biotherapeutics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Live Biotherapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Epidemiology of Clostridium Difficile Infection
• 5.3. Insights on Trends in the U.S. Burden of Clostridioides Difficile Infection
• 5.4. Porters' Five Forces Analysis

6. Global Live Biotherapeutics Market Analysis and Forecast, By Therapeutic Area

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Therapeutic Area, 2020-2034
  • 6.3.1. Gastrointestinal Disorders
  • 6.3.2. Metabolic Disorders
  • 6.3.3. Dermatological Diseases
  • 6.3.4. Others
• 6.4. Market Attractiveness By Therapeutic Area

7. Global Live Biotherapeutics Market Analysis and Forecast, By Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Route of Administration, 2020-2034
  • 7.3.1. Oral
  • 7.3.2. Rectal
  • 7.3.3. Others (Topical etc.)
• 7.4. Market Attractiveness By Route of Administration

8. Global Live Biotherapeutics Market Analysis and Forecast, By Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Distribution Channel, 2020-2034
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Attractiveness By Distribution Channel

9. Global Live Biotherapeutics Market Analysis and Forecast, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Live Biotherapeutics Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Therapeutic Area, 2020-2034
  • 10.2.1. Gastrointestinal Disorders
  • 10.2.2. Metabolic Disorders
  • 10.2.3. Dermatological Diseases
  • 10.2.4. Others
• 10.3. Market Value Forecast By Route of Administration, 2020-2034
  • 10.3.1. Oral
  • 10.3.2. Rectal
  • 10.3.3. Others (Topical etc.)
• 10.4. Market Value Forecast By Distribution Channel, 2020-2034
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast By Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Therapeutic Area
  • 10.6.2. By Route of Administration
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Live Biotherapeutics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Therapeutic Area, 2030-2034
  • 11.2.1. Gastrointestinal Disorders
  • 11.2.2. Metabolic Disorders
  • 11.2.3. Dermatological Diseases
  • 11.2.4. Others
• 11.3. Market Value Forecast By Route of Administration, 2030-2034
  • 11.3.1. Oral
  • 11.3.2. Rectal
  • 11.3.3. Others (Topical etc.)
• 11.4. Market Value Forecast By Distribution Channel, 2030-2034
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast By Country, 2030-2034
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Therapeutic Area
  • 11.6.2. By Route of Administration
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country

12. Asia Pacific Live Biotherapeutics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Therapeutic Area, 2031-2034
  • 12.2.1. Gastrointestinal Disorders
  • 12.2.2. Metabolic Disorders
  • 12.2.3. Dermatological Diseases
  • 12.2.4. Others
• 12.3. Market Value Forecast By Route of Administration, 2031-2034
  • 12.3.1. Oral
  • 12.3.2. Rectal
  • 12.3.3. Others (Topical etc.)
• 12.4. Market Value Forecast By Distribution Channel, 2031-2034
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast By Country, 2031-2034
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Therapeutic Area
  • 12.6.2. By Route of Administration
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country

13. Latin America Live Biotherapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Therapeutic Area, 2032-2034
  • 13.2.1. Gastrointestinal Disorders
  • 13.2.2. Metabolic Disorders
  • 13.2.3. Dermatological Diseases
  • 13.2.4. Others
• 13.3. Market Value Forecast By Route of Administration, 2032-2034
  • 13.3.1. Oral
  • 13.3.2. Rectal
  • 13.3.3. Others (Topical etc.)
• 13.4. Market Value Forecast By Distribution Channel, 2032-2034
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast By Country, 2032-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Therapeutic Area
  • 13.6.2. By Route of Administration
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country

14. Middle East & Africa Live Biotherapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Therapeutic Area, 2032-2034
  • 14.2.1. Gastrointestinal Disorders
  • 14.2.2. Metabolic Disorders
  • 14.2.3. Dermatological Diseases
  • 14.2.4. Others
• 14.3. Market Value Forecast By Route of Administration, 2032-2034
  • 14.3.1. Oral
  • 14.3.2. Rectal
  • 14.3.3. Others (Topical etc.)
• 14.4. Market Value Forecast By Distribution Channel, 2032-2034
  • 14.4.1. Hospital Pharmacies
  • 14.4.2. Retail Pharmacies
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast By Country, 2032-2034
  • 14.5.1. GCC
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Therapeutic Area
  • 14.6.2. By Route of Administration
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Ferring Pharmaceuticals
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Seres Therapeutics
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Rebiotix Inc.
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. 4D Pharma
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Finch Therapeutics
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Vedanta Biosciences
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Synthetic Biologics
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. MaaT Pharma
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
  • 15.3.9. Enterome
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
  • 15.3.10. Second Genome
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis